Syndecan-1 as an independent risk factor for the incidence of adverse cardiovascular events in patients having stage C and D heart failure with non-ischemic dilated cardiomyopathy

Abstract Background Patients with heart failure (HF) having non-ischemic dilated cardiomyopathy (DCM) have high mortality rates. Syndecan-1 is reportedly associated with cardiac fibrosis and inflammation. This study explored the role of syndecan-1 in patients with non-ischemic DCM. Methods Patients with HF were prospectively enrolled. Comprehensive clinical and biochemical analysis were performed. All patients were followed up for composite of major adverse cardiac events of cardiovascular death and cardiac transplantation. Results We measured syndecan-1 levels in 96 patients with HF and non-ischemic DCM. The primary outcome was the 3-year major adverse cardiac events. Approximately, 71% of patients were men with mean age and LVEF of 51.08 ± 13.28 years and 31.90 ± 8.85%, respectively. Median syndecan-1 levels were 456.57 pg/ml (interquartile range, 244.93–1181.26 pg/ml). Multivariate Cox regression analysis for Model I (adjusted for age, sex) and II (adjusted for traditional confounding factors) revealed that baseline syndecan-1 remained an independent predictor of composite endpoint events (Model I HR, 1.10/100 pg/ml increase in syndecan-1 level, 95% CI, 1.04–1.16, P  = 0.0006; Model II HR, 1.10/100 pg/ml increase in syndecan-1 level, 95% CI, 1.03–1.18, P  = 0.0029). Kaplan Meier analysis based on syndecan-1 tertiles revealed that the top tertile was associated with reduced survival compare to that in middle and bottom tertiles ( P Conclusion In patients with HF and non-ischemic DCM, the syndecan-1 level is important in the assessment of risk of adverse clinical outcome, and syndecan-1 level is correlated with fibrosis and inflammatory biomarkers.